Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | HMA combination strategies in MDS: BLC2, CD47 & TIM-3 inhibitors

Ciro Rinaldi • 5 May 2023
MDS 2023
Myelodysplastic Syndromes Antibodies Azacitidine Decitabine Magrolimab Sabatolimab Venetoclax

Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses promising drug combinations with hypomethylating agents (HMA) in patients with myelodysplastic syndromes (MDS). Prof. Rinaldi notably highlights the addition of the BCL2 inhibitor venetoclax, as well as CD47 and TIM-3 checkpoint inhibitors, all of which are currently being evaluated in Phase II and III trials. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ciro Rinaldi

1:12
The potential of targeting mutant calreticulin with antibodies in MPNs
Ciro Rinaldi • 3 Jun 2023
0:58
The potential of CAR-T therapy targeting mutant CALR in myelofibrosis & essential thrombocythemia
Ciro Rinaldi • 3 Jun 2023
1:22
Benefits and drawbacks of the IPSS-M
Ciro Rinaldi • 5 May 2023
1:16
The rationale for combining magrolimab with ruxolitinib in myelofibrosis
Ciro Rinaldi • 5 May 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals